34 results about "Gadolinium-Chelate" patented technology

The invention discloses a degradable dendritic macromolecule magnetic resonance contrast agent and a preparation method thereof. The degradable dendritic macromolecule magnetic resonance contrast agent is characterized in that a degradable dendritic macromolecule is used as a skeleton and micromolecular gadolinium chelates are connected to the degradable dendritic macromolecule so that the degradable dendritic macromolecule magnetic resonance contrast agent is formed. The degradable dendritic macromolecule magnetic resonance contrast agent has a relaxation rate of 17.4mM<-1>.s<-1> obviously higher than a relaxation rate of the common contrast agent, has a better MRI contrast effect, can be enriched in tumor tissue by enhanced permeation and retention effects of the degradable dendritic macromolecule magnetic resonance contrast agent, and improves MRI sensitivity and an early diagnosis level of cancers. The degradable dendritic macromolecule magnetic resonance contrast agent can be hydrolyzed by internal esterase catalysis and then is gradually discharged out of a human body so that the toxicity accumulation of gadolinium in a human body is avoided. The preparation method has simple processes, can be controlled easily and is suitable for industrial large-scale production.

The invention discloses an IL-13 modified gadolinium-containing chelate liposome targeted magnetic resonance imaging contrast agent, a preparation method and application thereof. The contrast agent is a liposome encapsulating a gadolinium chelate, and the surface of the liposome is modified with IL-13. Its preparation method is to prepare the liposome film first, then add the gadolinium chelate into the container containing the liposome film, and with the assistance of ultrasonic waves, the liposome film wraps the gadolinium chelate to form a gadolinium-containing chelate multilamellar liposomes; the surface of multilamellar liposomes encapsulating gadolinium chelates was modified with thiolated IL‑13. The contrast agent of the present invention can pass through the blood-brain barrier, deliver to tumor lesion sites and specifically bind to it. Therefore, this contrast agent is targeted, can detect tumor lesions smaller than 2mm, and can be used for early detection of tumors.

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

The invention discloses a preparation method and biological application of T1-T1 synergistic effect gadolinium chelate manganous-manganic oxide nano particles. The preparation method and the biological application of the T1-T1 synergistic effect gadolinium chelate manganous-manganic oxide nano particles include that firstly manganeseacetylacetonate is combined, and then oleylamine is used as a solvent, a high-temperature pyrolysis method is used to combine oil solubility manganous-manganic oxide nano particles, and then a ligand exchange method is utilized to use alendronate to be exchanged on the surfaces of the manganous-manganic oxide nano particles, so that nano particles are formed, wherein the surfaces of the nano particles are provided with a large number of amino groups. Then, the surfaces of the amino groups are connected with diethylenetriamine pentaacetic acid, so that the surfaces of the nano particles are provided with a large number of carboxyl groups, and at last a chelate effect is utilized to enable the large number of carboxyl groups and gadolinium to be chelated. Therefore, gadolinium chelate manganous-manganic oxide nano particles are obtained. The preparation method is low in requirement for equipment, convenient for operated process, low in needed raw material cost, and nuisanceless in accessory products. And at last through in vitro and in vivo magnetic resonance imaging experimental testing, so that compared with independent manganese and independent gadolinium, T1 magnetic resonance imaging contrast effect is strengthened.

The invention discloses an MRI contrast agent with a chitosan derivative as a carrier and a preparation method thereof. The contrast agent comprises: polyethylene glycol-modified chitosan as the main body of the contrast agent; and a second-generation polyamidoamine dendrimer molecule mainly connected to the chitosan main chain with a gadolinium chelate; its preparation The method comprises: first providing polyethylene glycol-modified chitosan, then coupling the chelating ligand of gadolinium to the alkyne-modified second-generation polyamidoamine dendrimer, and then linking it to the chitosan, The contrast agent is obtained. The MRI contrast agent with the chitosan derivative as a carrier has good biocompatibility, is easy to biodegrade, and has a high relaxation rate. The preparation method is simple, the required reaction temperature is moderate, and it is easy to control.

The invention discloses a preparation method of a gadolinium-based magnetic resonance imaging contrast agent with tumor targeting and its biomedical application. The contrast agent can specifically bind to transferrin receptor 1 highly expressed on the surface of tumor cells, is composed of genetically engineered recombinant protein and gadolinium chelate, and has a higher activity than the commercial contrast agent Magnevist (Gd-DTPA). longitudinal relaxation rate. The present invention provides a comparison of the imaging effects of animal tumor models with Magnevist, indicating that the contrast agent in the present invention can achieve tumor-specific recognition and longer-term magnetic resonance imaging at a lower injection dose without repeated injections. The contrast agent in the present invention can be administered intravenously, and is applied to the early diagnosis of cancer, the further identification of tumor metastasis and the diagnosis of suspicious recurrence after operation.